Principal investigator: Gunnar Birgegård
Primary objective: To monitor long term safety of anagrelide (Xagrid)
Status: Ongoing in most European countries. Inclusion stopped April 30 2009.
Research support: Shire
Study design: Observational study of 1000 patients on Xagrid and 2000 patients on other therapies, mainly hydroxycarbamide. Patients are followed for 5+5 years. Clinical outcome of ET therapy with regards to blood counts as well as clinical predefined events are registered every 6 months.
Inclusion criteria: ET patients receiving cytoreductive therapy for ET. Patients can be newly diagnosed or continuing their pre-prescibed medication of ET. Informed consent.
Exclusion criteria: Participation in other studies with experimental agents.
Contact person: Gunnar Birgegård